Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (Nasdaq: PRAX) has announced the granting of restricted stock unit awards to four new non-executive employees. The Compensation Committee of Praxis' Board of Directors approved these grants on April 1, 2025, under the company's 2024 Inducement Plan.
The awards cover an aggregate of 8,763 shares of common stock and will vest in four equal annual installments, contingent upon continued employment. These equity awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously Praxis employees.
Praxis Precision Medicines (Nasdaq: PRAX) ha annunciato l'assegnazione di premi in azioni riservate a quattro nuovi dipendenti non esecutivi. Il Comitato Compensi del Consiglio di Amministrazione di Praxis ha approvato questi premi il 1° aprile 2025, nell'ambito del Piano di Induzione 2024 dell'azienda.
I premi coprono un totale di 8.763 azioni ordinarie e saranno acquisiti in quattro rate annuali uguali, a condizione di un impiego continuativo. Questi premi azionari sono stati concessi come incentivi all'assunzione in conformità con Nasdaq Listing Rule 5635(c)(4), specificamente progettati per i nuovi assunti che non erano precedentemente dipendenti di Praxis.
Praxis Precision Medicines (Nasdaq: PRAX) ha anunciado la concesión de premios de unidades de acciones restringidas a cuatro nuevos empleados no ejecutivos. El Comité de Compensación de la Junta Directiva de Praxis aprobó estas concesiones el 1 de abril de 2025, bajo el Plan de Inducción 2024 de la empresa.
Los premios abarcan un total de 8,763 acciones ordinarias y se adquirirán en cuatro cuotas anuales iguales, condicionadas a la continuidad del empleo. Estos premios de acciones se otorgaron como incentivos laborales de acuerdo con Nasdaq Listing Rule 5635(c)(4), diseñados específicamente para nuevos empleados que no eran anteriormente empleados de Praxis.
프락시스 프리시전 메디슨스 (Nasdaq: PRAX)는 네 명의 새로운 비임원 직원에게 제한된 주식 단위 보상을 부여한다고 발표했습니다. 프락시스 이사회 보상위원회는 2025년 4월 1일에 이 보상을 승인하였으며, 이는 회사의 2024 유인 계획에 따라 이루어졌습니다.
이 보상은 총 8,763주의 보통주를 포함하며, 지속적인 고용 조건에 따라 4회의 동등한 연간 할부로 분할 지급됩니다. 이러한 주식 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 새로운 직원에게 제공되며, 이전에 프락시스의 직원이 아니었던 사람들을 위해 특별히 설계되었습니다.
Praxis Precision Medicines (Nasdaq: PRAX) a annoncé l'octroi de récompenses en unités d'actions restreintes à quatre nouveaux employés non exécutifs. Le Comité de Rémunération du Conseil d'Administration de Praxis a approuvé ces attributions le 1er avril 2025, dans le cadre du Plan d'Induction 2024 de l'entreprise.
Les récompenses concernent un total de 8 763 actions ordinaires et seront acquises en quatre versements annuels égaux, sous réserve d'une continuité d'emploi. Ces récompenses en actions ont été accordées comme incitations à l'emploi conformément à Nasdaq Listing Rule 5635(c)(4), spécifiquement conçues pour les nouvelles recrues qui n'étaient pas auparavant des employés de Praxis.
Praxis Precision Medicines (Nasdaq: PRAX) hat die Gewährung von beschränkten Aktieneinheiten an vier neue nicht-executive Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstands von Praxis genehmigte diese Zuwendungen am 1. April 2025 im Rahmen des Induktionsplans 2024 des Unternehmens.
Die Zuwendungen umfassen insgesamt 8.763 Aktien des Stammkapitals und werden in vier gleichen jährlichen Raten fällig, abhängig von einer fortgesetzten Anstellung. Diese Aktienzuwendungen wurden als Anreiz zur Beschäftigung gemäß Nasdaq Listing Rule 5635(c)(4) gewährt, die speziell für neue Mitarbeiter entwickelt wurden, die zuvor keine Mitarbeiter von Praxis waren.
- None.
- None.
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 8,763 shares of its common stock to four new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to each employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
How many shares were granted in Praxis Precision Medicines' (PRAX) April 2025 inducement awards?
What is the vesting schedule for PRAX's April 2025 inducement grants?
Who received the PRAX stock awards in April 2025?
Under which plan were PRAX's April 2025 inducement grants issued?
